Phase 2 results were positive for ILYX-002, a topical immunomodulator for moderate to severe dry eye disease associated with systemic autoimmune or inflammatory conditions, according to a press release from Iolyx Therapeutics.
“What’s amazing about ILYX-002 is that it’s a potent broad-spectrum anti-inflammatory that is targeted to a lot of the very specific pathways that are involved in dry eye,” Houman Hemmati, MD, PhD, head of medical at Iolyx, told Healio. “It targets very specific pathways such as [Th17/Th1] and, as a result of that, is really a tailor-made,